Minute Insight: Abbott Touts 14-Day FreeStyle Libre 3 Data

Shortly after the FDA approved Abbott's FreeStyle Libre 3 continuous glucose monitor system, the company announced new clinical data showing that it is the most accurate 14-day CGM system available.

Minute Insight
• Source: Informa/Alamy

Clinical data presented at the American Diabetes Association (ADA) conference in New Orleans support's Abbott’s claim that its FreeStyle Libre 3 system is the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall mean absolute relative difference (MARD).

Clinical data from a 100-patient, 14-day non-randomized study, presented by Abbott at the ADA meeting, showed FreeStyle Libre 3...

More from Minute Insights

More from Medtech Insight